

DOI: <https://doi.org/10.56936/18290825-2023.17.3-20>**MYOCARDIAL INFARCTION AT A YOUNG AGE: ANALYSIS OF CLINICAL CASES FROM THE DUPLEX REGISTRY DATABASE****GAISENOK O.V.**

Department of General Cardiology and Internal Medicine, United Hospital with Outpatient Clinic, Moscow, Russia

*Received 14.02.2022; accepted for printing 5.06.2023***ABSTRACT**

The objective of this study was to analyze clinical cases of myocardial infarction occurring at a young age within a sample of patients from the Duplex registry database (n=2548), to assess the prevalence of major risk factors and comorbid conditions. Specifically, patients under the age of 45 were selected (n=351).

Patients who experienced post-myocardial infarction were identified using data from clinical and anamnestic records, in accordance with the International Classification of Diseases, 10th Revision - their proportion was 0.85% (n=3) (all male patients; mean age 35 ± 1.4 years). Two out of three were smokers and had other traditional risk factors such as hypertension, dyslipidemia and overweight. In addition, patients had important comorbid diseases: morbid obesity, lymphogranulomatosis, hepatitis with transformation to liver cirrhosis. All of them had confirmed atherosclerosis of the arteries of the lower extremities. Probably one of the main precipitating factors for myocardial infarction development in them was a hereditary predisposition due to a burdened family history, although none of them met the Dutch Lipid Clinics Network criteria for familial hyperlipidemia and none of them underwent genetic testing.

A better understanding of risk factors and pathophysiological pathways in young adults may improve strategies for both preventing and treating myocardial infarction in this patient group. Raising awareness can help identify young individuals at higher risk and determine primary prevention strategies.

However, the identification of patients with premature coronary artery disease by screening for traditional risk factors does not effectively identify patients at risk prior to the diagnosis of myocardial infarction. Additional studies are needed to evaluate new risk factors and apply additional imaging techniques so that these patients can be identified before myocardial infarction occurs.

KEYWORDS: myocardial infarction, young adults, family history of cardiovascular disease, risk factors, male patients, hyperlipidemia, hereditary predisposition.

INTRODUCTION

Despite advancements in combating cardiovascular diseases, the occurrence of myocardial infarction (MI) in younger individuals has not exhibited a decrease over time [Singh A *et al*, 2018; Wu

W *et al*, 2020; Sagris M *et al*, 2021] and its diagnosis in a patient under the age of 45 has ceased to surprise the medical community and is no longer considered rare. An age analysis of MI patients in

CITE THIS ARTICLE AS:

Gaisenk O.V. (2023). Myocardial Infarction At A Young Age: Analysis Of Clinical Cases From The Duplex Registry Database; The New Armenian Medical Journal, vol.17(3), p 20-25; <https://doi.org/10.56936/18290825-2023.17.3-20>

ADDRESS FOR CORRESPONDENCE:

Oleg V. Gaisenk, MD, PhD
Department of General Cardiology and Internal Medicine
United Hospital with Outpatient Clinic, 6 Michurinsky av., Moscow 119285, Russia
Tel. +74991478221
E-mail: ovg.07@bk.ru

the Lyubertsy Infarct Survival Study (LISS)-3 ACS registry LISS registry showed that the youngest age recorded was 26 years [Martsevich S et al., 2011, 2017]. It is likely that psychological factors along with behavioral and hereditary factors can play a large role in this [Wiesbauer F et al., 2009; Chait R et al., 2011]. A stressful lifestyle, irregular working hours, the economic crisis, inflation, the risk of job loss, global cataclysms, the COVID-19 pandemic [Gaisenk O, 2020] and other causes lead to the formation of a state of chronic stress, hypersympathicotonia and excessive production of catecholamin's. Which in turn trigger pathophysiological mechanisms that activate the young patient's early movement along the path of the cardiovascular disease continuum, initiated with an increase in heart rate and blood pressure [Dzau V et al, 2006; Custodis F et al., 2013].

Stress can have its negative impact on the cardiovascular system through lipid factors and not only through its effects on the nervous system and neurohumoral factors thus leading to lipid disorders [Gaisenk O, 2015]. Studies confirm that workplace stress is associated with an increased risk of atherosclerosis [Liu Y et al, 2015]. The INTERHEART study confirmed the important role of stress in the development of MI (RR 2.67) [Rosengren A et al., 2004].

Being in a state of chronic stress, in turn, increases the likelihood of alcohol consumption and smoking, which are included in this process as additional risk factors. The Shiga Subclinical Atherosclerosis Epidemiological Study confirmed that smokers have a significantly higher risk of developing atherosclerosis not only in the coronary arteries but also in the arteries of other vascular basins compared to never smokers [Hisamatsu T et al., 2016]. An analysis of data from the Cardiovascular Risk in Young Finns Study showed that alcohol consumption has proatherogenic effects in young healthy adults [Juonala M et al., 2009]. Irrational nutrition with an increase in the consumption of fats and easily digestible carbohydrates leads to an increase in the prevalence of diabetes mellitus, obesity and dyslipidemia among such patients [Wu W et al., 2020]. In addition, it should be noted that patients with cardiovascular diseases were most at risk of various complications during the COVID-19 pandemic [Gaisenk O, 2020].

Present study aimed to analyze clinical cases of myocardial infarction at a young age among a sample of patients under 45 years of age according to the Duplex registry database and to assess the presence of major risk factors and comorbid conditions in them.

MATERIAL AND METHODS

The Duplex registry database (n=2548) was used for this study. The detailed methodology for conducting this registry was described in previous publications [Gaisenk O, Drapkina O, 2022]. Patients under 45 years of age were selected based on the WHO criteria for young people (n=351). Identification of patients after MI was carried out among them based on the data of clinical and anamnestic status and international classification of diseases 10th revision - their proportion was 0.85% (n=3).

RESULTS

A detailed study of the clinical and anamnestic status of patients with myocardial infarction at a young age was carried out (all male patients; mean age 35 ± 1.4 years). We analyzed such indicators as age, features of coronary lesions, the presence of family history of cardiovascular disease, the presence of arterial hypertension, smoking, overweight, dyslipidemia, the presence of atherosclerosis of other localizations, ongoing statin therapy, the presence of major comorbidities with the calculation of the Charlson polymorbidity index. The obtained data are presented in table.

DISCUSSION

Many publications have been devoted to the study of the problem of early MI in recent years. The emphasis in most studies began to be given not only to the analysis of known risk factors, but also to the search for new determinants in the development of this disease. It is also interesting to pay attention to the prevalence of this pathology. In most studies, the vast majority of patients with early MI were men [Martsevich S et al., 2011; Wittlinger T et al., 2020], which was also shown in our case series (all male patients; mean age 35 ± 1.4 years). Although the detection of this pathology in women was studied in a single work /or in a few works. For example, in a Malay study that

TABLE

Clinical and anamnestic status of patients with myocardial infarction at a young age

Signs	Patients with myocardial infarction at a young age		
	N1	N2	N3
Age of enrollment (years old)	36	37	44
Age at the time of MI (years old)	33	37	35
Coronary artery lesions	CA - 80%	ADA - 96%, CA - 95%, OMB - 75%	n.a.
Coronary artery stenting	CA	ADA, CA and OMB stenting	n.a.
A burdened family history of cardiovascular disease	+	++	n.a.
Hypertension	+	-	+
Smoking	+	-	+
Overweight	++	-	+
Hyperlipidemia	-	+	+
Carotid atherosclerosis	-	-	+
Lower limb arteries atherosclerosis	+	+	+
Statin therapy	+	+	-
Comorbidities	Morbid obesity	Lymphogranulomatosis	Hepatitis with cirrhosis transformation
Charlson index	1 point	3 points	5 points
Predicted 10-year survival	96%	77%	21%

NOTES: MI – myocardial infarction; ADA - anterior descending artery; CA - circumflex artery; OMB - obtuse marginal branch; n.a. - not available

analyzed the course of MI in young women (mean age 39 ± 4.68 years). At the same time, the authors stated the prevailing role of genetic predisposition, since young Malay women have significantly higher rates of family history of premature coronary artery disease [Venkatasen P *et al.*, 2019].

The percentage of patients who suffered MI among all young patients was 0.85% in our study. Data analysis from the prospective Dresden Registry of Myocardial Infarction (2005-2014) showed that patients under the age of 40 years made up 2% of the entire study cohort. At the same time, young patients experienced ST-elevation myocardial infarction more often than myocardial infarction without ST segment elevation (70% vs 30%) [Wittlinger T *et al.*, 2020].

It is important to analyze new risk factors for myocardial infarction at a young age, which should be paid attention to by the practitioner when collecting anamnesis. Androgenic-anabolic steroid abuse is known to increase the risk of heart disease including acute MI. Chest pain in young patients secondary to MI is not uncommon, and therefore an important consideration in assessing the history is the review of medications, including anabolic steroid use. Athletes, bodybuilders and others who use anabolic steroids should be monitored by physicians in order to promptly detect complications associated with steroid use [Samreen F *et al.*, 2021]. In addition to androgenic anabolic steroids, MI in young patients may be associated with cannabis and cocaine use [Sagris M *et al.*, 2021].

Although smoking is a known risk factor for MI, most physicians and patients interpret it in relation to cigarette smoking. One recent study confirmed that this also applies to waterpipe smoking [Abed MA *et al.*, 2018].

None of the patients in our case series used steroids, cannabis, cocaine or waterpipe smoking. Although 2 out of 3 were smokers and had other traditional risk factors such as arterial hypertension, dyslipidemia, overweight (2/3, table). In addition, patients had important comorbid diseases: morbid obesity, lymphogranulomatosis, hepatitis with transformation into liver cirrhosis. All of them had confirmed atherosclerosis of arteries of the lower extremities in a duplex scanning. Probably one of the main precipitating factors for MI development in them was a hereditary predisposition due to a burdened family history, although none of them met the Dutch Lipid Clinics Network criteria for familial hyperlipidemia and none of them underwent genetic testing.

An Austrian study found evidence that the familial-combined hyperlipidemia phenotype appears to be a major risk factor for MI at a very young age. The familial-combined hyperlipidemia phenotype was associated with a 24-fold increase in the adjusted risk of MI in patients younger than 40 years of age in the study (95% CI 7.5-81, $P < 0.001$). Very-low-density lipoprotein cholesterol and non-high-density lipoprotein-cholesterol of all lipid parameters were most strongly associated with MI [Wiesbauer F *et al.*, 2009].

Speaking about the possibilities of laboratory

diagnostics of predisposition to early development of MI, interesting data were obtained in an Indian study [Gupta M *et al.*, 2020]. In this pilot study relative telomere length was found to be significantly shorter in young MI patients (31-45 years old) compared to healthy controls ($p < 0.0001$). Thus, in the future, telomere length analysis may be a potential screening tool for young patients who do not have the usual risk factors.

Ambroziak M. and co-authors (2018) in their study noted the role of adiponectin and its genetic variants in the risk of developing premature myocardial infarction at a young age.

The absence and/or underestimation of available standard risk factors leads to late prescription of statin therapy. At the same time, screening for traditional risk factors usually does not effectively identify young patients at risk before the diagnosis of MI [Chait R *et al.*, 2012].

A group of authors noted in their study that the vast majority of adults with a history of MI at a young age did not meet the current thresholds for statin therapy prior to MI, as recommended by the American College of Cardiology/American Heart Association 2013 and the Prevention Task Force US Services 2016 [Singh A *et al.*, 2018]. These results highlight the need for better risk assessment tools for young people.

CONCLUSION

It is necessary to further study the pathogenetic mechanisms underlying the development of myocardial infarction among young individuals. It is known that young patients with MI are more likely to be smokers, obese, lead a sedentary lifestyle and drink alcohol.

Younger than older MI patients are more likely to be male and have familial-combined hyperlipidemia. A better understanding of risk factors and pathophysiological pathways in young adults may improve strategies for both preventing and treating myocardial infarction in this patient group. Raising awareness can help identify young individuals at higher risk and determine primary prevention strategies.

However, evaluating patients for premature coronary artery disease by screening for traditional risk factors does not effectively identify patients at risk prior to the diagnosis of myocardial infarction. Additional studies are needed to evaluate new risk factors and apply additional imaging techniques so that these patients can be identified before myocardial infarction occurs.

REFERENCES

1. Abed MA, Eshah NF, Moser DK (2018). Risk profile of myocardial infarction in young versus older adults. *Heart Lung*. 47(3): 226-230 DOI: 10.1016/j.hrtlng.2018.03.002
2. Ambroziak M, Kolanowska M, Bartoszewicz Z, Budaj A (2018). Adiponectin gene variants and decreased adiponectin plasma levels are associated with the risk of myocardial infarction in young age. *Gene*. 642: 498-504 DOI: 10.1016/j.gene.2017.11.064
3. Chait R, Ramineni R, Fender EA (2012). Precocious virulent coronary atherosclerosis in the very young. *Cardiol Young*. 22(2): 184-187 DOI: 10.1017/S1047951111001156
4. Custodis F, Reil JC, Laufs U, Böhm M (2013). Heart rate: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum. *J Cardiol*. 62(3): 183-187 DOI: 10.1016/j.jjcc.2013.02.018
5. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE., *et al* (2006). The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). *Circulation*. 114(25): 2850-2870 DOI: 10.1161/CIRCULATIONAHA.106.655688
6. Gaisenok O (2020). Pandemic of Fear or what Statistics Hide: Patients with Cardiovascular Disease are at Increased Risk During COVID-19. *International Cardiovascular Forum Journal*. 21: 2-6 DOI: 10.17987/icfj.v21i0.711
7. Gaisenok O, Drapkina O (2022). Gender differences in the detection of carotid atherosclerosis.

- rosis: DUPLEX registry cross-sectional study results. *Monaldi Arch Chest Dis.* 92(4): 2128 DOI: 10.4081/monaldi.2022.2128
8. *Gaisenk OV (2015).* Assessing the impact of workplace stress on total cholesterol and low density lipoprotein levels: the example of the application of log-linear analysis in medical studies with small samples. *European Journal of Biomedical and Life Sciences.* 4: 49-56
 9. *Gupta MD, Miglani M, Bansal A, Jain V, Arora S., et al (2020).* Telomere length in young patients with acute myocardial infarction without conventional risk factors: A pilot study from a South Asian population. *Indian Heart J.* 72(6): 619-622 DOI: 10.1016/j.ihj.2020.11.006
 10. *Hisamatsu T, Miura K, Arima H, Kadota A, Kadowaki S., et al (2016).* Smoking, Smoking Cessation, and Measures of Subclinical Atherosclerosis in Multiple Vascular Beds in Japanese Men. *J Am Heart Assoc.* 5(9): e003738 DOI: 10.1161/JAHA.116.003738
 11. *Juonala M, Viikari JS, Kähönen M, Laitinen T, Taittonen L, et al (2009).* Alcohol consumption is directly associated with carotid intima-media thickness in Finnish young adults: the Cardiovascular Risk in Young Finns Study. *Atherosclerosis.* 204(2): e93-8 DOI: 10.1016/j.atherosclerosis.2008.11.021
 12. *Liu YL, Szklo M, Davidson KW, Bathon JM, Giles JT (2015).* Differential Association of Psychosocial Comorbidities with Subclinical Atherosclerosis in Rheumatoid Arthritis. *Arthritis Care Res (Hoboken).* 67(10): 1335-1344 DOI: 10.1002/acr.22635
 13. *Martsevich S. Yu.; Semenova Y. V.; Kutishenko N. P.; Zagebelnyy A. V.; Ginzburg M. L. (2017).* Awareness of cardiovascular disease, its risk factors, and its association with attendance at outpatient clinics in acute coronary syndrome patients. *Integrative Medicine Research,* (), S221342201730080X-. doi:10.1016/j.imr.2017.06.003
 14. *Martsevich SYu, Ginsburg ML, Kutishenko NP, Deev AD, Fokina AV., et al (2011).* LIS Study (Lyubertsy Study of mortality in patients after acute myocardial infarction): the patients' portrait. *Cardiovascular Therapy and Prevention.* 10(6): 89-93 DOI:10.15829/1728-8800-2011-6-89-93
 15. *Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M., et al (2004).* Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. *Lancet.* 364(9438): 953-962 DOI: 10.1016/S0140-6736(04)17019-0
 16. *Sagris M, Antonopoulos AS, Theofilis P, Oikonomou E, Siasos G., et al (2021).* Risk factors profile of young and older patients with Myocardial Infarction. *Cardiovasc Res.* cvab264 DOI: 10.1093/cvr/cvab264
 17. *Samreen F, Popal U, Qutrio Baloch ZA (2021).* Anabolic Steroid-Induced Myocardial Infarction in a Young Male. *Cureus.* 13(2): e13054 DOI: 10.7759/cureus.13054
 18. *Singh A, Collins BL, Gupta A, Fatima A, Qamar A., et al (2018).* Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry. *J Am Coll Cardiol.* 71(3): 292-302 DOI: 10.1016/j.jacc.2017.11.007
 19. *Venkatason P, Zubairi YZ, Zaharan NL, Wan Ahmad WA, Hafidz MI., et al (2019).* Characteristics and short-term outcomes of young women with acute myocardial infarction in Malaysia: a retrospective analysis from the Malaysian National Cardiovascular Database registry. *BMJ Open.* 9(11): e030159 DOI: 10.1136/bmjopen-2019-030159
 20. *Wiesbauer F, Blessberger H, Azar D, Goliasch G, Wagner O., et al (2009).* Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or =40 years of age). *Eur Heart J.* 30(9): 1073-1079 DOI: 10.1093/eurheartj/ehp051
 21. *Wittlinger T, Seifert C, Simonis G, Gerlach M, Strasser RH (2020).* Prognosis in myocardial infarction of young patients: Results of a prospective registry. *Int J Cardiol.* 300: 1-6 DOI: 10.1016/j.ijcard.2019.10.037
 22. *Wu WY, Berman AN, Biery DW, Blankstein R (2020).* Recent trends in acute myocardial infarction among the young. *Curr Opin Cardiol.* 35(5): 524-530 DOI: 10.1097/HCO.0000000000000781



CONTENTS

4. **AVAGYAN M., KAGER L., ZOHRABYAN D., SAFARYAN L., TANANYAN A., MAMUNTS D., PAPYAN R., ARAKELYAN J., VARDEVANYAN H., MKHITARYAN S., TAMAMYAN G., BARDAKHCHYAN S.**
SECONDARY MALIGNANCY IN GIANT CELL TUMOR OF THE SKULL BASE AFTER DENOSUMAB TREATMENT: CASE REPORT
11. **NURDIANA N., WINARSIH S., TRI ENDHARTI A., HANDAYANI S.**
HOLOTHURIN AND CASPOFUNGIN-INDUCED ALTERATIONS IN TOLL-LIKE RECEPTOR 4 EXPRESSION IN THE VAGINA OF RATTUS NORVEGICUS WISTAR WITH CANDIDIASIS
20. **GAISENOK O.V.**
MYOCARDIAL INFARCTION AT A YOUNG AGE: ANALYSIS OF CLINICAL CASES FROM THE DUPLEX REGISTRY DATABASE
25. **GAVANJI S., BAKHTARI A., BAGHSHAHI H., BADRIPOUR N., HAMAMI CHAMGORDANI Z.**
CYTOTOXICITY EFFECTS OF ETHANOLIC EXTRACT OF PUNICA GRANATUM VAR. PLENIFLORA ON MCF-7 COMPARED WITH L929 CELLS
31. **BANJARI I., HAN S., AL-TAWIL N., ĆORIĆ N., BALKIĆ WIDMANN J.**
STROKE RISK ASSESSMENT AND DIET-RELATED RISK FACTORS – COMPARISON OF TWO CITIES FROM BOSNIA AND HERZEGOVINA
40. **SANI M., HOKMABADI M.E.**
THE EFFECT OF GALLIC ACID AS A PLANT POLYPHENOL COMPOUND ON OXIDATIVE STRESS INDUCED IN ALZHEIMER'S NEURODEGENERATIVE DISEASE
51. **EBRAHIMZADEH KOUR B., JAMBARANG S., KARIMPOUR F., HOSSEINI S.E., RAMAZANI V., MOZAFFARI-KHOSRAVI H.**
INFLAMMATORY AND STRESS OXIDATIVE IMPROVING POTENTIAL OF CHROMIUM SUPPLEMENTATION: PROTOCOL FOR A SYSTEMATIC REVIEW AND META ANALYSIS OF RANDOMIZED CLINICAL TRIALS
59. **GHOCHIKYAN T.V., MARTIRYAN A.I., TADEVOSYAN L.G., PETROSYAN I.A., GALSTYAN A.S., SAMVELYAN M.A.**
HYPOTENSIVE AND ANTIOXIDANT PROPERTIES OF GAMMA-HYDROXY ACID HYDRAZIDES
66. **HOVHANNISYAN H.G., PASHAYAN M.M., BARSEGHYAN A.H., GRIGORYAN G.G., GABOYAN E.H., DANIELYAN L.V.**
HEALTH PROMOTING POTENTIALS OF ARMENIAN FUNCTIONAL SOUR MILK "NARINE" AND ITS STARTER LACTOBACILLUS HELVETICUS MDC 9602
74. **SANI M., HOKMABADI M.E.**
DESCRIBING THE GINGER PLANT AND ITS EFFECTIVE INGREDIENTS ALONG WITH ITS THERAPEUTIC PROPERTIES IN VARIOUS COMPLICATIONS
84. **REVENKO N.A., SIZOVA O.A., MARCHUKOVA A.YU., KALADZE N.N., ITSKOVA E.A.**
EFFECTIVENESS OF COMBINED REHABILITATION THERAPY IN KIDS WITH METABOLIC SYNDROME
91. **KUMAR-ANMOL K., CHANDRASEKARAN M.S., ADARSHA G.K., NITIN BHAT N., RAO R.**
A RARE CASE OF THROMBOTIC THROMBOCYTOPENIC PURPURA COMPLICATED BY MACROVASCULAR EVENTS
95. **ALHOQAIL A.A., ALSAAD S.M.**
ASSOCIATION BETWEEN POSTPARTUM DEPRESSION AND SLEEP QUALITY AND ITS RELATED FACTORS
105. **MANUKYAN N.V., TAMAMYAN G.N., AVETISYAN A.A., JILAVYAN S.A., SAGHATELYAN T.S.**
A REVIEW OF CHALLENGES AND PROSPECTS OF MOBILE MAMMOGRAPHY SCREENING IN DEVELOPING COUNTRIES
119. **QADAH W.A.**
THE IMPACT OF SOCIAL MEDIA ADDICTION ON SELF-ESTEEM AND LIFE SATISFACTION AMONG STUDENTS IN KING ABDUL AZIZ UNIVERSITY AND FAKEEH COLLEGE FOR MEDICAL SCIENCES IN JEDDAH: CROSS-SECTIONAL STUDY



The Journal is founded by
Yerevan State Medical
University after M. Heratsi.



Rector of YSMU

Armen A. Muradyan

Address for correspondence:

Yerevan State Medical University
2 Koryun Street, Yerevan 0025,
Republic of Armenia

Phones:

(+37410) 582532 YSMU

(+37493 588697 Editor-in-Chief

Fax: (+37410) 582532

E-mail: namj.ysmu@gmail.com, ysmiu@mail.ru

URL: <http://www.ysmu.am>

*Our journal is registered in the databases of Scopus,
EBSCO and Thomson Reuters (in the registration process)*



SCOPUS



EBSCO
REUTERS

Copy editor: Tatevik R. Movsisyan

Printed in "LAS Print" LLC
Director: Suren A. Simonyan
Armenia, 0023, Yerevan,
Acharyan St. 44 Bulding,
Phone: (+374 10) 62 76 12,
E-mail: las.print@yahoo.com

Editor-in-Chief

Arto V. Zilfyan (Yerevan, Armenia)

Deputy Editors

Hovhannes M. Manvelyan (Yerevan, Armenia)

Hamayak S. Sisakyan (Yerevan, Armenia)

Executive Secretary

Stepan A. Avagyan (Yerevan, Armenia)

Editorial Board

Armen A. Muradyan (Yerevan, Armenia)

Drastamat N. Khudaverdyan (Yerevan, Armenia)

Levon M. Mkrtchyan (Yerevan, Armenia)

Foregin Members of the Editorial Board

Carsten N. GUTT (Memmingen, Germany)

Muhammad MIFTAHUSSURUR (Indonesia)

Alexander WOODMAN (Dharhan, Saudi Arabia)

Hesam Adin Atashi (Tehran, Iran)

Coordinating Editor (for this number)

NAREK V. MANUKYAN (Yerevan, Armenia)

Editorial Advisory Council

Ara S. Babloyan (Yerevan, Armenia)

Aram Chobanian (Boston, USA)

Luciana Dini (Lecce, Italy)

Azat A. Engibaryan (Yerevan, Armenia)

Ruben V. Fanarjyan (Yerevan, Armenia)

Gerasimos Filippatos (Athens, Greece)

Gabriele Fragasso (Milan, Italy)

Samvel G. Galstyan (Yerevan, Armenia)

Arthur A. Grigorian (Macon, Georgia, USA)

Armen Dz. Hambardzumyan (Yerevan, Armenia)

Seyran P. Kocharyan (Yerevan, Armenia)

Aleksandr S. Malayan (Yerevan, Armenia)

Mikhail Z. Narimanyan (Yerevan, Armenia)

Levon N. Nazarian (Philadelphia, USA)

Yumei Niu (Harbin, China)

Linda F. Noble-Haeusslein (San Francisco, USA)

Arthur K. Shukuryan (Yerevan, Armenia)

Suren A. Stepanyan (Yerevan, Armenia)

Gevorg N. Tamamyanyan (Yerevan, Armenia)

Hakob V. Topchyan (Yerevan, Armenia)

Alexander Tsiskaridze (Tbilisi, Georgia)

Konstantin B. Yenkovyan (Yerevan, Armenia)

Peijun Wang (Harbin, China)